# Exzeo Group, Inc.: financial statements, quarterly

XZO · NYSE · CIK 1873951 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xzo.md) · [Financials](/companies/xzo/financials.md) · [Filings](/companies/xzo/filings.md) · [Insiders](/companies/xzo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xzo/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [29.1](/filings/0001193125-25-315970.md) | [44.5 d](/filings/0001193125-26-076686.md) | [52.4](/filings/0001193125-26-211961.md) | [56.1](/filings/0001193125-26-340267.md) | [55.2](/filings/0001193125-25-315970.md) | [53.3 d](/filings/0001193125-26-076686.md) | [55.5](/filings/0001193125-26-211961.md) | [57.8](/filings/0001193125-26-340267.md) |
| Cost of revenue | $m | [18.0](/filings/0001193125-25-315970.md) | [25.8 d](/filings/0001193125-26-076686.md) | [23.6](/filings/0001193125-26-211961.md) | [22.5](/filings/0001193125-26-340267.md) | [21.4](/filings/0001193125-25-315970.md) | [18.4 d](/filings/0001193125-26-076686.md) | [22.8](/filings/0001193125-26-211961.md) | [20.9](/filings/0001193125-26-340267.md) |
| Gross profit | $m | [11.1](/filings/0001193125-25-315970.md) | [18.7 d](/filings/0001193125-26-076686.md) | [28.8](/filings/0001193125-26-211961.md) | [33.6](/filings/0001193125-26-340267.md) | [33.8](/filings/0001193125-25-315970.md) | [34.9 d](/filings/0001193125-26-076686.md) | [32.7](/filings/0001193125-26-211961.md) | [36.8](/filings/0001193125-26-340267.md) |
| Research and development | $m | [1.7](/filings/0001193125-25-315970.md) | [1.5 d](/filings/0001193125-26-076686.md) | [2.2](/filings/0001193125-26-211961.md) | [2.4](/filings/0001193125-26-340267.md) | [2.5](/filings/0001193125-25-315970.md) | [1.8 d](/filings/0001193125-26-076686.md) | [2.3](/filings/0001193125-26-211961.md) | [2.4](/filings/0001193125-26-340267.md) |
| Selling, general and administrative | $m | [2.6](/filings/0001193125-25-315970.md) | [1.5 d](/filings/0001193125-26-076686.md) | [2.7](/filings/0001193125-26-211961.md) | [3.0](/filings/0001193125-26-340267.md) | [3.9](/filings/0001193125-25-315970.md) | [6.2 d](/filings/0001193125-26-076686.md) | [5.2](/filings/0001193125-26-211961.md) | [5.8](/filings/0001193125-26-340267.md) |
| Operating income | $m | [6.7](/filings/0001193125-25-315970.md) | [15.6 d](/filings/0001193125-26-076686.md) | [23.8](/filings/0001193125-26-211961.md) | [28.1](/filings/0001193125-26-340267.md) | [27.3](/filings/0001193125-25-315970.md) | [26.8 d](/filings/0001193125-26-076686.md) | [25.1](/filings/0001193125-26-211961.md) | [28.5](/filings/0001193125-26-340267.md) |
| Income tax | $m | [1.7](/filings/0001193125-25-315970.md) | [4.1 d](/filings/0001193125-26-076686.md) | [6.2](/filings/0001193125-26-211961.md) | [7.2](/filings/0001193125-26-340267.md) | [7.2](/filings/0001193125-25-315970.md) | [6.9 d](/filings/0001193125-26-076686.md) | [7.2](/filings/0001193125-26-211961.md) | [8.2](/filings/0001193125-26-340267.md) |
| Net income | $m | [5.3](/filings/0001193125-25-315970.md) | [11.7 d](/filings/0001193125-26-076686.md) | [18.0](/filings/0001193125-26-211961.md) | [21.7](/filings/0001193125-26-340267.md) | [21.2](/filings/0001193125-25-315970.md) | [22.0 d](/filings/0001193125-26-076686.md) | [20.4](/filings/0001193125-26-211961.md) | [23.3](/filings/0001193125-26-340267.md) |
| Diluted EPS | $ per share | [0.06](/filings/0001193125-25-315970.md) | not reported | [0.22](/filings/0001193125-26-211961.md) | [0.26](/filings/0001193125-26-340267.md) | [0.25](/filings/0001193125-25-315970.md) | not reported | [0.22](/filings/0001193125-26-211961.md) | [0.26](/filings/0001193125-26-340267.md) |
| Basic EPS | $ per share | [0.06](/filings/0001193125-25-315970.md) | not reported | [0.22](/filings/0001193125-26-211961.md) | [0.26](/filings/0001193125-26-340267.md) | [0.25](/filings/0001193125-25-315970.md) | not reported | [0.22](/filings/0001193125-26-211961.md) | [0.26](/filings/0001193125-26-340267.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [54.5](/filings/0001193125-26-076686.md) | not reported | not reported | [141](/filings/0001193125-25-315970.md) | [305](/filings/0001193125-26-340267.md) | [231](/filings/0001193125-26-211961.md) | [137](/filings/0001193125-26-340267.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [67.2](/filings/0001193125-26-076686.md) | not reported | not reported | [163](/filings/0001193125-25-315970.md) | [326](/filings/0001193125-26-340267.md) | [261](/filings/0001193125-26-211961.md) | [170](/filings/0001193125-26-340267.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [89.4](/filings/0001193125-26-076686.md) | not reported | not reported | [182](/filings/0001193125-25-315970.md) | [348](/filings/0001193125-26-340267.md) | [380](/filings/0001193125-26-211961.md) | [386](/filings/0001193125-26-340267.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [56.4](/filings/0001193125-26-076686.md) | not reported | not reported | [93.9](/filings/0001193125-25-315970.md) | [84.4](/filings/0001193125-26-340267.md) | [98.6](/filings/0001193125-26-211961.md) | [91.7](/filings/0001193125-26-340267.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [73.9](/filings/0001193125-26-076686.md) | not reported | not reported | [104](/filings/0001193125-25-315970.md) | [93.6](/filings/0001193125-26-340267.md) | [105](/filings/0001193125-26-211961.md) | [97.6](/filings/0001193125-26-340267.md) |
| Shareholders' equity | $m | [(43.1)](/filings/0001193125-26-076686.md) | [(25.3)](/filings/0001193125-26-076686.md) | [(2.2)](/filings/0001193125-25-315970.md) | [3.3](/filings/0001193125-25-315970.md) | [15.5](/filings/0001193125-26-076686.md) | [34.2](/filings/0001193125-26-340267.md) | [56.6](/filings/0001193125-26-340267.md) | [78.4](/filings/0001193125-25-315970.md) | [254](/filings/0001193125-26-340267.md) | [275](/filings/0001193125-26-211961.md) | [288](/filings/0001193125-26-340267.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [19.9 d](/filings/0001193125-26-076686.md) | [19.8](/filings/0001193125-26-211961.md) | [37.8 d](/filings/0001193125-26-340267.md) | [31.5 d](/filings/0001193125-25-315970.md) | [11.3 d](/filings/0001193125-26-076686.md) | [25.5](/filings/0001193125-26-211961.md) | [15.4 d](/filings/0001193125-26-340267.md) |
| Capital expenditure | $m | [0.6 d](/filings/0001193125-26-076686.md) | [0.8](/filings/0001193125-26-211961.md) | [0.5 d](/filings/0001193125-26-340267.md) | [1.2 d](/filings/0001193125-25-315970.md) | [0.4 d](/filings/0001193125-26-076686.md) | [0.3](/filings/0001193125-26-211961.md) | [0.2 d](/filings/0001193125-26-340267.md) |
| Share repurchases | $m | [0.0 d](/filings/0001193125-26-076686.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-315970.md) | [1.5 d](/filings/0001193125-26-076686.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.7](/filings/0001193125-25-315970.md) | [0.1](/filings/0001193125-26-211961.md) | [78.7](/filings/0001193125-26-340267.md) | [78.7](/filings/0001193125-25-315970.md) | [0.1](/filings/0001193125-26-211961.md) | [88.2](/filings/0001193125-26-340267.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 90,085,918 at 2026-07-31, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340267.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.